Selection of currently ongoing clinical trials evaluating CTLA4 or/and PD1/PD-L1 checkpoint blockade in combination with untargeted and targeted options including other immunotherapeutic approaches for pancreatic cancer as indicated. The gene discussed is CTLA4; the disease is familial pancreatic carcinoma.